Interleukin Profiling in Atopic Dermatitis and Chronic Nodular Prurigo.
Humans
Dermatitis, Atopic
/ metabolism
Prurigo
/ metabolism
Female
Adult
Male
Interleukin-13
/ metabolism
Interleukins
/ metabolism
Pruritus
/ metabolism
Middle Aged
Interleukin-4
/ metabolism
Chronic Disease
Skin
/ metabolism
Young Adult
Interleukin-13 Receptor alpha1 Subunit
/ metabolism
Interleukin-13 Receptor alpha2 Subunit
/ metabolism
atopic dermatitis
chronic pruritus
interleukin-13
interleukin-4
nodular prurigo
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
02 Aug 2024
02 Aug 2024
Historique:
received:
04
07
2024
revised:
29
07
2024
accepted:
29
07
2024
medline:
10
8
2024
pubmed:
10
8
2024
entrez:
10
8
2024
Statut:
epublish
Résumé
The clinical manifestations of atopic dermatitis (AD) and chronic nodular prurigo (CNPG) include pruritus and eczema/lesions, posing significant challenges for patients. Th2 cells and ILC2, marked by cytokine production-particularly IL-4/13-are crucial therapeutic targets. Despite displaying a dose-dependent lack of pruritus induction post-injection, IL-13 acts through the IL-13Rα1 and IL-13Rα2 receptor system. Our study focused on investigating ex vivo skin biopsies in AD (n = 17), CNPG (n = 14) and healthy controls (HC; n = 10), examining the gene expression landscape of interleukins linked with pruritus (IL-13, IL-4, IL-31) and their corresponding receptors. Compared to HC, results revealed a significant upregulation of
Identifiants
pubmed: 39126011
pii: ijms25158445
doi: 10.3390/ijms25158445
pii:
doi:
Substances chimiques
Interleukin-13
0
Interleukins
0
Interleukin-4
207137-56-2
IL31 protein, human
0
IL13 protein, human
0
Interleukin-13 Receptor alpha1 Subunit
0
IL13RA1 protein, human
0
Interleukin-13 Receptor alpha2 Subunit
0
IL4 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : FOR2690 and FOR5211
Organisme : Leo Pharma (Germany)
ID : IIS-TRALO-1540